Prescription pattern, short-term outcomes, and its determinants in patients with chronic kidney disease attending a tertiary care hospital
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 51 (1) , 55-60
Abstract
BACKGROUND: Chronic kidney disease (CKD) is a worldwide public health problem associated with an eight- to ten-fold increase in cardiovascular mortality. Among patients with CKD, on drug treatment, we aimed to determine the characteristics, etiology, patterns and rates of drug use, and outcomes and factors determining the outcomes at 6 months. METHODS: We conducted an observational follow-up study on inpatients with CKD at a tertiary care teaching hospital in South India. We collected data on patient characteristics, comorbidities, treatments at baseline, and treatments and outcomes at 6 months. We used Chi-squared tests and Cochran's Q-test to compare categorical variables, t-tests to compare continuous variables, and a multivariable logistic regression analysis to estimate the determinants of the outcome. RESULTS: We recruited 305 patients with the mean age 52.98 (+/- 14.89) years, 73.1% were male and 55.4% patients were from a lower-middle socioeconomic background. About 72.1% were in CKD Stage 5 and 37.0% had diabetic nephropathy. Antihypertensives (84.6%) were the most common drug class prescribed, followed by multivitamins (65.2%), proton-pump inhibitors (64.9%), and antidiabetic drugs (32.5%). There was no significant difference in rates of drug use over 6 months. Increased serum creatinine (odds ratio [OR]: 1.29 [1.04, 1.60]: P = 0.017) and lower estimated glomerular filtration rate (eGFR) (OR: 38.23 [3.92, 372.06]; P= 0.002) predicted progression of CKD, and antiplatelets reduced progression (OR: 0.278 [0.09, 0.85]; P= 0.026). CONCLUSION: Diabetic nephropathy was the most common cause of CKD. There was no change in treatments over 6 months. Low eGFR predicted progression and use of antiplatelets reduced progression of CKD. Large multicenter studies are needed to study the variability in patient characteristics, treatment and outcomes to obtain a national picture, and to enable policy changes.Keywords
This publication has 11 references indexed in Scilit:
- Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-AnalysisPLOS ONE, 2016
- Chronic kidney disease in low- and middle-income countriesNephrology Dialysis Transplantation, 2016
- The Effect of Calcium With or Without Calcitriol Supplementation on Renal Function in Patients With Hypovitaminosis D and Chronic Kidney DiseaseNephro-Urology Monthly, 2014
- Epidemiology and risk factors of chronic kidney disease in India – results from the SEEK (Screening and Early Evaluation of Kidney Disease) studyBMC Nephrology, 2013
- What do we know about chronic kidney disease in India: first report of the Indian CKD registryBMC Nephrology, 2012
- Medication prescribing patterns among chronic kidney disease patients in a hospital in Malaysia.2012
- The contribution of chronic kidney disease to the global burden of major noncommunicable diseasesKidney International, 2011
- Serum Creatinine, Cystatin C, and -Trace Protein in Diagnostic Staging and Predicting Progression of Primary Nondiabetic Chronic Kidney DiseaseClinical Chemistry, 2010
- Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial InfarctionCirculation, 2004
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004